AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) has announced the commencement of ImmunoPass clinical trials. ImmunoPass is the company’s rapid point-of-care test that semi-quantitatively measures COVID-19 neutralizing antibody levels....
AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) has completed a study focusing on the performance of its NeuCovix™ rapid test measuring the neutralizing levels of anti-COVID-19 antibodies. NeuCovix™ accurately...
Axim Biotechnologies Inc. (OTCMKTS:AXIM), an investment company of Medical Marijuana Inc. (OTCMKTS:MJNA), has announced the expansion of its research division by establishing an ultra-modern laboratory in...
Axim Biotechnologies Inc (OTCQB:AXIM) issued business highlights for Q3 2017. The company reported that it held bi-annual board meeting in the month of July, during which...
In the imminent 12-18 months, Axim Biotechnologies Inc (OTCMKTS:AXIM) intends to accomplish a number of clinical programs. The company intends to conclude the open-label Phase 2...
As per a report issued by New Frontier Data, permitted cannabis sales in California are estimated to reach $2.8 billion in 2017, with a compound yearly...
SECFilings.com published an article covering the ophthalmology segment and Axim Biotechnologies Inc (OTCMKTS:AXIM) cannabinoid-based therapies. International ophthalmology revenue is expected to grow at a compound annual...
Axim Biotechnologies Inc (OTCMKTS:AXIM) reported that the USPTO has issued a Notice of Allowance for a patent that claims the application of an ophthalmic solution comprising...
SECFilings.com reported the publication of an article showcasing Axim Biotechnologies Inc (OTCMKTS:AXIM) clinical progress and portfolio in light of Zynerba’s Phase II Cannabidiol gel patch failure....
Axim Biotechnologies Inc (OTCMKTS:AXIM) has finalized a Services Deal with an Israel-based CRO to commence a clinical proof of concept trial with its Hemp and Gabapentin...